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128 (54%) were in the intervention group and 111 (46%) were in the control group. Out of these, 95 of the intervention and 93 of the control patients completed the study and only 53 (intervention group)and 46 (control group), respectively, had both baseline and study HbA1c measurements. The patients in the intervention group had a median age of 65 years (range: 44 -86) and 55% were female. The patients in the control group had a median age of 66 years (range: 41 -88) and 57% were female.
Study design
The study was based on a prospective cohort study, with control and intervention groups matched on demographic and diabetes-related characteristics. Each of the control and intervention groups was based in three settings: rural and metropolitan community pharmacy settings and a hospital diabetes clinic. There were 9 intervention pharmacists and 20 control pharmacists. The patients in both groups were followed up for 9 months. Fifty-one patients dropped out of the study for various reasons, but they did not differ significantly from those who remained in the study in any of the characteristics considered.
Analysis of effectiveness
All of the patients included in the study were accounted for in the analysis. The primary health outcome was the HbA1c level. The authors reported that the HbAlc measurement gives an average of the blood glucose level over the past 6 to 8 weeks. The change in mean HbA1c, the change in the proportion of patients who achieved a clinically significant reduction in HbA1c (>1%) and the proportion of patients with an HbA1c greater than 7% were calculated before and after the study. No statistically significant differences between the groups were found in terms of age, gender and prognostic features. However, the authors reported that a higher proportion of patients in the control group were managed through the diabetes clinic (the results were not shown).
Effectiveness results
For the intervention group, the mean levels of HbA1c were 7.40 (standard deviation, SD=1.34) at 9 months' follow-up versus 7.86 (SD=1.37) at baseline. This represented a statistically significant reduction in HbA1c levels of 0.46%, (p=0.02).
For the control group, the mean levels of HbA1c were 7.38 (SD=1.08) at 9 months' follow-up versus 7.41 (SD=1.14) at baseline. This represented a reduction in HbA1c levels of 0.03%, (p=0.81).
A greater proportion (28%) of patients achieved a clinically significant reduction in HbA1c (>/=1%) in the intervention group than in the control group (15%). However, this difference was not statistically significant, (p=0.12).
There was a significant reduction in the proportion of participants with elevated HbA1c (>7%) at follow-up in the intervention group, (p=0.03), which was not achieved in the control group, (p=0.51).
Clinical conclusions
The specialised service resulted in a significant reduction in HbA1c.
Measure of benefits used in the economic analysis
The authors used the mean reduction in HbA1c levels achieved by the specialised care approach, compared with standard care, as the measure of health benefit.
Direct costs
The direct costs included in the analysis were those to the health care service. These costs were those associated with service provision, diabetes-related health care and medications. The costs associated with service provision included the total time the pharmacist spent in providing the service (i.e. in initial and follow-up visits and time spent conducting medication reviews), the cost of print-outs of blood glucose levels given to patients, and the cost and time taken with telephone calls. The costs of diabetes-related health care included visits to the general practitioner, specialist, emergency department visits and hospital admissions.
The unit costs were derived from multiple sources. Pharmacist time was cost using the average award rate of an experienced community pharmacist. The health care resource costs were based on the Australian Medicare Benefit schedule fees. The cost of hospitalisation was based on the Casemix Standards for New South Wales. The costs of medications were derived from the Dispensed Price for Maximum Quantity listed in the Schedule of Pharmaceutical Benefits (PBS) minus the contribution to the PBS price made by each general patient and concession cardholder patient. Discounting was not relevant, as all the costs were incurred during 9 months, and hence was not performed. The study reported the average costs. The price year was 2001.
Statistical analysis of costs
The mean and SDs of the costs of both groups were calculated. Ninety-five per cent confidence intervals (CIs) were then calculated using Student's t-distribution.
Indirect Costs
The indirect costs were not included in the analysis, as these costs were not borne directly by the health care system.
Currency
Australian dollars (Aus$).
Sensitivity analysis
To assess the robustness of the study results, a scenario sensitivity analysis with best-and worst-case scenarios was performed. The parameters varied were the pharmacist's time spent providing the service and the cost of the medication, as these were considered to be the most uncertain values. In the best-case scenario, it was assumed that there was no difference in the cost of medications between groups at baseline and at the end of the study. In the worstcase scenario, the cost of medication was based on the full price listed, with no contribution made by the patient, as this would be the highest price the government would pay for medications.
Estimated benefits used in the economic analysis
The mean reduction in HbA1c levels achieved by the specialised service over standard care was 0.43% (95% CI: 0.34 -0.52).
Cost results
The mean cost per patient in the intervention group was Aus$1,821.12 (SD=120.35) versus Aus$1,437.81 (SD=164.55) in the control group. This represented an increase in costs of Aus$394 (95% CI: 46.16 -717.46) per patient.
Synthesis of costs and benefits
The net cost and the net effectiveness of the specialised service, compared with the standard service, were calculated and expressed as a cost-effectiveness ratio (i.e. the additional cost per benefit gained). Thus, the incremental cost per 1% reduction in mean HbA1c for the specialised service compared with standard care was Aus$891.42 (95% CI: 94.54 -2,110.18).
In the best-case scenario, assuming that the costs of medications were the same, the cost of achieving a 0.43% reduction in HbA1c was Aus$166.72. In the worst-case scenario, where the government was assumed to pay all medication costs, the cost of achieving a 0.43% reduction in HbA1c was Aus$535.13.
